Hemoglobinuria, Paroxysmal - 24 Studies Found
Completed |
: Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria :
: 1999-10-18 :
|
Completed |
: Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors :
|
Enrolling by invitation |
: The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population : Bone Marrow Failure Syndrome : 2015-03-05 :
|
Enrolling by invitation |
: Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation :
: 2012-12-06 : Drug: Eltrombopag From day +1, start eltrombopag 100 mg/d. |
Active, not recruiting |
: Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device :
|
Recruiting |
: Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2017-03-08 : Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d |
Not yet recruiting |
: ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2017-02-14 :
|
Recruiting |
: A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2017-02-01 : Drug: ACH-0144471 ACH-0144471 will be administered to all patients enrolled in the study. |
Recruiting |
: Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2017-01-20 : Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d |